Easy to brush over RAC's preclinical results by dismissing them as "just preclinical" when you don't understand the context and history of Zantrene and about RAC's strategy in pivoting/repurposing it. Doesn't help when it is a first in class drug with no baseline level of understanding/awareness. It actually takes time to understand the RAC opportunity and the market is full of people with goldfish attention spans looking for the next sugar rush.
Easy to brush over RAC's preclinical results by dismissing them...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |